These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

229 related articles for article (PubMed ID: 2156735)

  • 1. Presence of highly selective receptors for PACAP (pituitary adenylate cyclase activating peptide) in membranes from the rat pancreatic acinar cell line AR 4-2J.
    Buscail L; Gourlet P; Cauvin A; De Neef P; Gossen D; Arimura A; Miyata A; Coy DH; Robberecht P; Christophe J
    FEBS Lett; 1990 Mar; 262(1):77-81. PubMed ID: 2156735
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Characterization of vasoactive intestinal peptide/pituitary adenylate cyclase-activating peptide receptors in human benign hyperplastic prostate.
    Solano RM; Carmena MJ; Carrero I; Cavallaro S; Roman F; Hueso C; Travali S; Lopez-Fraile N; Guijarro LG; Prieto JC
    Endocrinology; 1996 Jul; 137(7):2815-22. PubMed ID: 8770902
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Structural requirements for the binding of the pituitary adenylate-cyclase-activating peptide to receptors and adenylate-cyclase activation in pancreatic and neuronal membranes.
    Gourlet P; Woussen-Colle MC; Robberecht P; de Neef P; Cauvin A; Vandermeers-Piret MC; Vandermeers A; Christophe J
    Eur J Biochem; 1991 Jan; 195(2):535-41. PubMed ID: 1997328
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Receptor occupancy and adenylate cyclase activation in AR 4-2J rat pancreatic acinar cell membranes by analogs of pituitary adenylate cyclase-activating peptides amino-terminally shortened or modified at position 1, 2, 3, 20, or 21.
    Robberecht P; Gourlet P; De Neef P; Woussen-Colle MC; Vandermeers-Piret MC; Vandermeers A; Christophe J
    Mol Pharmacol; 1992 Aug; 42(2):347-55. PubMed ID: 1325033
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Characterization of binding sites for VIP-related peptides and activation of adenylate cyclase in developing pancreas.
    Le Meuth V; Farjaudon N; Bawab W; Chastre E; Rosselin G; Guilloteau P; Gespach C
    Am J Physiol; 1991 Feb; 260(2 Pt 1):G265-74. PubMed ID: 1847591
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The activation of adenylate cyclase by pituitary adenylate cyclase activating polypeptide (PACAP) via helodermin-preferring VIP receptors in human SUP-T1 lymphoblastic membranes.
    Gourlet P; De Neef P; Woussen-Colle MC; Vandermeers A; Vandermeers-Piret MC; Robberecht P; Christophe J
    Biochim Biophys Acta; 1991 Jul; 1066(2):245-51. PubMed ID: 1649637
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Pharmacological, molecular and functional characterization of vasoactive intestinal polypeptide/pituitary adenylate cyclase-activating polypeptide receptors in the rat pineal gland.
    Simonneaux V; Kienlen-Campard P; Loeffler JP; Basille M; Gonzalez BJ; Vaudry H; Robberecht P; Pévet P
    Neuroscience; 1998 Aug; 85(3):887-96. PubMed ID: 9639281
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Characterization of a guanosine-nucleotide-binding-protein-coupled receptor for pituitary adenylate-cyclase-activating polypeptide on plasma membranes from rat brain.
    Schäfer H; Schwarzhoff R; Creutzfeldt W; Schmidt WE
    Eur J Biochem; 1991 Dec; 202(3):951-8. PubMed ID: 1662620
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Antagonistic properties are shifted back to agonistic properties by further N-terminal shortening of pituitary adenylate-cyclase-activating peptides in human neuroblastoma NB-OK-1 cell membranes.
    Vandermeers A; Vandenborre S; Hou X; de Neef P; Robberecht P; Vandermeers-Piret MC; Christophe J
    Eur J Biochem; 1992 Sep; 208(3):815-9. PubMed ID: 1327769
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The novel VIP-like hypothalamic polypeptide PACAP interacts with high affinity receptors in the human neuroblastoma cell line NB-OK.
    Cauvin A; Buscail L; Gourlet P; De Neef P; Gossen D; Arimura A; Miyata A; Coy DH; Robberecht P; Christophe J
    Peptides; 1990; 11(4):773-7. PubMed ID: 2172943
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Investigation of the interaction of VIP binding sites with VIP and PACAP in human brain.
    Suda K; Smith DM; Ghatei MA; Bloom SR
    Neurosci Lett; 1992 Mar; 137(1):19-23. PubMed ID: 1320752
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Interaction of ovine pituitary adenylate cyclase-activating peptide (PACAP-38) with rat lung membranes.
    Bitar KG; Coy DH
    Peptides; 1993; 14(3):621-7. PubMed ID: 8392724
    [TBL] [Abstract][Full Text] [Related]  

  • 13. PACAP and VIP stimulate enzyme secretion in rat pancreatic acini via interaction with VIP/PACAP-2 receptors: additive augmentation of CCK/carbachol-induced enzyme release.
    Schmidt WE; Seebeck J; Höcker M; Schwarzhoff R; Schäfer H; Fornefeld H; Morys-Wortmann C; Fölsch UR; Creutzfeldt W
    Pancreas; 1993 Jul; 8(4):476-87. PubMed ID: 8103217
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A cloned frog vasoactive intestinal polypeptide/pituitary adenylate cyclase-activating polypeptide receptor exhibits pharmacological and tissue distribution characteristics of both VPAC1 and VPAC2 receptors in mammals.
    Alexandre D; Anouar Y; Jegou S; Fournier A; Vaudry H
    Endocrinology; 1999 Mar; 140(3):1285-93. PubMed ID: 10067855
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Characterization of a common VIP-PACAP receptor in human small intestinal epithelium.
    Salomon R; Couvineau A; Rouyer-Fessard C; Voisin T; Lavallée D; Blais A; Darmoul D; Laburthe M
    Am J Physiol; 1993 Feb; 264(2 Pt 1):E294-300. PubMed ID: 8383439
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Pituitary adenylate cyclase activating polypeptide receptors are present on small cell lung cancer cells.
    Moody TW; Zia F; Makheja A
    Peptides; 1993; 14(2):241-6. PubMed ID: 8387187
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Receptors for pituitary adenylate cyclase-activating peptide in human liver.
    Guijarro LG; Rodriguez-Henche N; García-López E; Noguerales F; Dapena MA; Juarranz MG; Prieto JC
    J Clin Endocrinol Metab; 1995 Aug; 80(8):2451-7. PubMed ID: 7629241
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Pituitary adenylate cyclase-activating polypeptide/vasoactive intestinal polypeptide receptor subtypes are differently expressed in rat transplanted pituitary tumours (SMtTW) and in the normal gland.
    Vertongen P; Delhase M; Rajas F; Trouillas J; Hooghe-Peters E; Svoboda M; Robberecht P
    J Mol Endocrinol; 1996 Jun; 16(3):239-48. PubMed ID: 8782082
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Interaction of lipophilic VIP derivatives with recombinant VIP1/PACAP and VIP2/PACAP receptors.
    Gourlet P; Rathé J; De Neef P; Cnudde J; Vandermeers-Piret MC; Waelbroeck M; Robberecht P
    Eur J Pharmacol; 1998 Jul; 354(1):105-11. PubMed ID: 9726637
    [TBL] [Abstract][Full Text] [Related]  

  • 20. PACAP and VIP receptors in rat liver membranes.
    Robberecht P; Gourlet P; Cauvin A; Buscail L; De Neef P; Arimura A; Christophe J
    Am J Physiol; 1991 Jan; 260(1 Pt 1):G97-102. PubMed ID: 1846275
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.